Intellia Therapeutics, Inc.
NTLA
$9.06
$0.9611.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.27% | 104.76% | -42.54% | 771.57% | -24.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.27% | 104.76% | -42.54% | 771.57% | -24.02% |
| Cost of Revenue | -27.69% | -19.81% | -3.06% | 7.25% | -3.98% |
| Gross Profit | 34.87% | 29.09% | -10.72% | 6.22% | 1.61% |
| SG&A Expenses | 3.59% | -4.08% | -6.70% | 11.90% | 52.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.60% | -14.90% | -3.85% | 8.22% | 7.53% |
| Operating Income | 23.00% | 20.89% | -5.97% | 2.46% | -10.42% |
| Income Before Tax | 25.34% | 31.11% | -6.42% | 2.47% | -11.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.34% | 31.11% | -6.42% | 2.47% | -11.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.34% | 31.11% | -6.42% | 2.47% | -11.04% |
| EBIT | 23.00% | 20.89% | -5.97% | 2.46% | -10.42% |
| EBITDA | 25.06% | 21.20% | -6.12% | 2.58% | -10.36% |
| EPS Basic | 31.56% | 35.60% | 1.81% | 13.38% | 2.55% |
| Normalized Basic EPS | 27.61% | 24.26% | -2.14% | 15.45% | 4.76% |
| EPS Diluted | 31.56% | 35.60% | 1.81% | 13.38% | 2.55% |
| Normalized Diluted EPS | 27.61% | 24.26% | -2.14% | 15.45% | 4.76% |
| Average Basic Shares Outstanding | 9.09% | 6.97% | 8.37% | 12.60% | 13.94% |
| Average Diluted Shares Outstanding | 9.09% | 6.97% | 8.37% | 12.60% | 13.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |